Utilisation of home nursing to mitigate the impact of COVID-19 on the conduct of the gantenerumab graduate trials
The opportunity to receive study drug at home is particularly important to Alzheimer’s trial participants, who are vulnerable to COVID-19. As a result of the COVID-19 pandemic, home nursing capabilities of the GRADUATE trials were expanded to continue assessing the safety and efficacy of subcutaneous gantenerumab. Here, we analyse the use of home nursing before and during the peak phases of the COVID-19 pandemic. To conclude, there was a substantial increase in the use of home administration of subcutaneous gantenerumab during the COVID-19 pandemic.
{{assetTitle}}
{{assetDescription}}
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.